BioPharmSignal logoBioPharmSignal

Biotech News

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Pliant Therapeutics (PLRX)Pliant TherapeuticsClinical readout

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune

Related news

PLRXPliant Therapeutics2026-04-18 17:31 EST

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

PLRXPliant Therapeutics2026-03-18 13:00 EST

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

View all latest news

Pliant Therapeutics

Integrin-Targeted Drug Discovery Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery. PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the αvβ8 and αvβ1...

Recent company news

PLRXPliant Therapeutics2026-08-18 12:30 EST

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

PLRXPliant Therapeutics2026-08-11 20:05 EST

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PLRXPliant Therapeutics2026-07-13 12:30 EST

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

PLRXPliant Therapeutics2026-05-21 21:30 EST

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

PLRXPliant Therapeutics2026-05-11 20:05 EST

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Stock data

Close
1.10 USD
Market cap
71.83M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States